Skip to content

Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01748929
Enrollment
1010
Registered
2012-12-13
Start date
2014-02-24
Completion date
2016-09-16
Last updated
2017-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal Diseases, Parasitic

Keywords

Global Health, Deworming, Postpartum, Soil-Transmitted Helminths, Pregnant Women

Brief summary

Women of reproductive age are considered a high-risk group for worm infections by the World Health Organization. Maternal infection and anemia contribute to infant malnutrition by affecting milk quality and quantity, and duration of exclusive breastfeeding. To date, no study has investigated the health benefits of postpartum deworming to infants or mothers. A randomized controlled trial will be conducted in Peru to investigate the effectiveness of integrating deworming into routine postpartum care. The primary measure of effect will be infant weight gain between birth and six months of age. Other infant and maternal health indicators will also be ascertained.

Interventions

DRUGAlbendazole
DRUGPlacebo

Sponsors

McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* Deliver at Hospital Iquitos * Plan to reside in Iquitos or neighbouring area for the next 24 months * Able to communicate in Spanish

Exclusion criteria

* Deliver multiples * Delivery a stillborn or an infant with a serious congenital medical condition * Transfered to another hospital prior to discharge

Design outcomes

Primary

MeasureTime frame
Mean (± standard deviation) weight gain (kg)Change between birth and six months of age

Secondary

MeasureTime frameDescription
Maternal hemoglobin levels and anemia1, 6, 12, 24 months following birth
Breastfeeding practices1, 6, 12, 24 months following birthThe prevalence of current, exclusive, predominant and partial breastfeeding will be used to assess breastfeeding practices. In accordance with WHO criteria, infants will be considered as exclusively breastfed if they ingest only breast milk (excluding vitamins and medications); considered as predominantly breastfed if, in addition to breast milk, they also ingest water, juice, teas, vitamins or medications, and considered as partially breastfed if their primary nutrition source is other than breast milk.
Maternal energy levels1, 6, 12, 24 months following birthMaternal energy levels will be measured using an adapted 5-item version of the Fatigue Assessment Scale (FAS) (Michielsen et al. 2004). This scale assesses symptoms of physical and cognitive fatigue.
Infant morbidity1, 6, 12, 24 months following birth
Breast milk quality1 and 6 months following birthMean concentrations of key breast milk quality indicators (i.e. macronutrients, immunological factors, vitamins, and minerals) will be used to assess breast milk quality.
Breast milk quantity transferred from mother to infant1 and 6 months following birth
Maternal STH infection1 and 6 months following birth

Countries

Peru

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026